The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.
The group discusses anticipated advancements in Bruton tyrosine kinase inhibitor (BTKi) therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). A key goal is converting continuous BTKi treatment into time-limited approaches through combinations or stopping criteria based on deep responses. This could improve quality of life and reduce financial burdens compared with indefinite therapy.Incorporating assessment of minimal residual disease as a trigger for discontinuation is an exciting strategy being explored in trials.
The panelists highlight the potential of leveraging precision medicine through mutational profiling and cytogenetics to guide upfront BTKi selection and sequencing. This allows customization based on a patient’s molecular features rather than a one-size-fits-all approach. Expanding the options for noncovalent BTKis that can overcome specific resistance mutations will enable optimal treatment sequencing tailored to a patient’s mutational profile when disease relapse occurs.
Overall, the group is optimistic about integrating predictive biomarkers, combination strategies, and novel targeted agents to usher in an era of personalized BTKi therapy in CLL and SLL. This offers hope for maximizing treatment outcomes while minimizing toxicity burdens for patients.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More